SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 3,430.57 |
| Enterprise Value ($M) | 6,489.87 |
| Book Value ($M) | 4,319.40 |
| Book Value / Share | 31.65 |
| Price / Book | 0.79 |
| NCAV ($M) | -2,846.40 |
| NCAV / Share | -20.86 |
| Price / NCAV | -1.21 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.02 |
| Return on Assets (ROA) | -0.02 |
| Return on Equity (ROE) | -0.04 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.34 |
| Current Ratio | 2.38 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2,481.90 |
| Assets | 9,647.70 |
| Liabilities | 5,328.30 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 4,373.40 |
| Operating Income | 314.60 |
| Net Income | -171.80 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 362.90 |
| Cash from Investing | 78.80 |
| Cash from Financing | -611.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Price T Rowe Associates Inc /md/ | 5.80 | 9,919.21 | |
| 13G | State Street Corp | 5.10 | ||
| 13G | Dimensional Fund Advisors Lp | 5.10 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 159,694 | 671,463 | 23.78 | |
| 187,201 | 967,081 | 19.36 | |
| 113,838 | 554,714 | 20.52 | |
| 112,485 | 695,418 | 16.18 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| OGN – Organon & Co. | PBH – Prestige Consumer Healthcare Inc. |
| PFE – Pfizer Inc. | QGEN – Qiagen N.V. |
| RCUS – Arcus Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io